In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

Background Millions of people worldwide suffer from hepatitis C, which can lead to severe
liver disease, liver cancer, and death. Direct‐acting antivirals (DAAs), eg sofosbuvir, are …

Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease
worldwide [1]. The long-term impact of HCV infection is highly variable, ranging from minimal …

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

One of the most exciting developments in antiviral research has been the discovery of the
direct-acting antivirals (DAAs) that effectively cure chronic hepatitis C virus (HCV) infections …

Background Virologic and safety outcomes of ombitasvir/paritaprevir/ritonavir±dasabuvir±
ribavirin (OBV/PTV/r±DSV±RBV) therapy have shown high sustained virologic response …

Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in
Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy …

Highlights•DAAs for HCV treatment include protease (NS3/4A) inhibitors, RNA-dependent
polymerase (NS5B) inhibitors and NS5A inhibitors.•The combination of DAA owning to …

Importance A 2013 review for the US Preventive Services Task Force (USPSTF) of hepatitis
C virus (HCV) screening found interferon-based antiviral therapy associated with increased …

Background New direct-acting antiviral agents (DAAs) approved for the treatment of patients
infected by Hepatitis C virus (HCV) are well tolerated and increase sustained virological …